| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 696 | 2017 |
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 … A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ... The Lancet Oncology 17 (3), 367-377, 2016 | 678 | 2016 |
| Mir-34: a new weapon against cancer? G Misso, MT Di Martino, G De Rosa, AA Farooqi, A Lombardi, V Campani, ... Molecular therapy Nucleic acids 3, 2014 | 599 | 2014 |
| Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma M Fulciniti, P Tassone, T Hideshima, S Vallet, P Nanjappa, SA Ettenberg, ... Blood, The Journal of the American Society of Hematology 114 (2), 371-379, 2009 | 482 | 2009 |
| BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells P Tassone, P Tagliaferri, A Perricelli, S Blotta, B Quaresima, ML Martelli, ... British journal of cancer 88 (8), 1285-1291, 2003 | 459 | 2003 |
| HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells E Carbone, P Neri, M Mesuraca, MT Fulciniti, T Otsuki, D Pende, V Groh, ... Blood 105 (1), 251-258, 2005 | 430 | 2005 |
| Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells L Catley, E Weisberg, T Kiziltepe, YT Tai, T Hideshima, P Neri, P Tassone, ... Blood 108 (10), 3441-3449, 2006 | 407 | 2006 |
| MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches N Amodio, L Raimondi, G Juli, MA Stamato, D Caracciolo, P Tagliaferri, ... Journal of hematology & oncology 11, 1-19, 2018 | 322 | 2018 |
| Dysfunctional T regulatory cells in multiple myeloma RH Prabhala, P Neri, JE Bae, P Tassone, MA Shammas, CK Allam, ... Blood 107 (1), 301-304, 2006 | 299 | 2006 |
| Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Clinical cancer research 18 (22), 6260-6270, 2012 | 267 | 2012 |
| Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy P Correale, MS Rotundo, MT Del Vecchio, C Remondo, C Migali, ... Journal of immunotherapy 33 (4), 435-441, 2010 | 255 | 2010 |
| Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullà, M Rossi, ... Clinical Cancer Research 19 (8), 2096-2106, 2013 | 241 | 2013 |
| Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti, M Manzoni, E Taiana, ... Leukemia 32 (9), 1948-1957, 2018 | 239 | 2018 |
| Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor … YL Wu, Y Cheng, J Zhou, S Lu, Y Zhang, J Zhao, DW Kim, RA Soo, ... The Lancet Respiratory Medicine 8 (11), 1132-1143, 2020 | 233 | 2020 |
| miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ... Journal of cellular physiology 228 (7), 1506-1515, 2013 | 215 | 2013 |
| Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro P Tassone, P Tagliaferri, C Viscomi, C Palmieri, M Caraglia, ... British journal of cancer 88 (12), 1971-1978, 2003 | 210 | 2003 |
| Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic “dark matter” K Grillone, C Riillo, F Scionti, R Rocca, G Tradigo, PH Guzzi, S Alcaro, ... Journal of Experimental & Clinical Cancer Research 39, 1-19, 2020 | 208 | 2020 |
| Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines P Tassone, S Forciniti, E Galea, G Morrone, MC Turco, V Martinelli, ... Leukemia 14 (5), 841-844, 2000 | 201 | 2000 |
| miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ... Cell death & disease 3 (11), e436-e436, 2012 | 198 | 2012 |
| Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells MF Romano, A Lamberti, P Tassone, F Alfinito, S Costantini, F Chiurazzi, ... Blood, The Journal of the American Society of Hematology 92 (3), 990-995, 1998 | 189 | 1998 |
Pierosandro Tagliaferriprofessore di oncologia medica Università magna graecia di CatanzaroVerifisert e-postadresse på unicz.it
